Atossa Therapeutics Pioneers Pathway in Breast Cancer Therapy: A Synergistic Potential Unveiled’
SEATTLE, WA’ - Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company devoted to addressing significant unmet medical needs in oncology, continues to make strides in the field of breast cancer treatment. The company’s recent announcements demonstrate noteworthy progress and a strong foothold in the development of revolutionary oncological therapies focused predominantly on breast cancer.
Karisma-Endoxifen Clinical Trial Reaches Landmark Completion’
On May 15, 2024, Atossa declared a significant milestone with the last patient, last dose in its Phase 2 Karisma-Endoxifen clinical trial. This pivotal moment indicates that all patients enrolled in the trial have concluded their designated course of the innovative therapy, clearing the way for the critical evaluation of clinical data.
Endoxifen, the investigational drug in spotlight, is designed to potentially treat estrogen receptor-positive (ER+) breast cancer, promising an innovative approach for premenopausal women confronted with this challenging diagnosis. The successful culmination of this trial phase positions Atossa to analyze comprehensive results and continue advancing (Z)-endoxifen’s therapeutic journey.
Five-Year Success in FDA-Approved Expanded Access Program’
Adding to Atossa’s triumphs, on March 19, 2024, the company provided an impressive five-year update on a breast cancer patient treated with (Z)-endoxifen under the FDA-approved expanded access program.
The premenopausal ER+/HER2- patient, who received both neoadjuvant and adjuvant (Z)-endoxifen therapy, remains cancer-free. Furthermore, no significant safety or tolerability issues were reported throughout the five-year duration. This success story underscores (Z)-endoxifen’s potential as a long-term treatment option, reinforcing confidence in its safety and efficacy profile.
EVANGELINE Clinical Trial Data to be Showcased at AACR Annual Meeting’
In parallel, Atossa is set to present data from the Phase 2 EVANGELINE (Endoxifen Versus exemestANe GosEreLIn) study at the American Association for Cancer Research (AACR) Annual Meeting, scheduled from April 5-10, 2024, in San Diego, California. The EVANGELINE study is meticulously investigating (Z)-endoxifen as a neoadjuvant treatment specifically for premenopausal women diagnosed with ER+/HER2- breast cancer.
The presentation will feature data from the 40mg pharmacokinetic (PK) run-in cohort, promising meaningful insights into (Z)-endoxifen’s absorption, distribution, metabolism, and excretion in patients. This presentation not only highlights continued progress but also places Atossa in the spotlight among leading cancer research institutions.
Impact on Atossa Therapeutics’
Collectively, these milestones reflect positively on Atossa Therapeutics, lending credence to their focused and innovative approach in breast cancer treatment. Successfully completing the Phase 2 Karisma-Endoxifen trial and the favorable long-term patient outcomes from the expanded access program bolster the company’s credibility and potential market position. Moreover, presenting at a prestigious forum such as the AACR Annual Meeting enhances their visibility in the oncology research community, potentially attracting collaborations, partnerships, and investments.
Atossa’s ongoing clinical developments underscore their commitment to pioneering effective treatments and improving the prognosis for breast cancer patients globally. As the data from these trials is analyzed and shared, Atossa Therapeutics stands at a promising crossroads, poised to deliver transformative therapeutic solutions in oncological care.
Comments